Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

AEZS opened at $1.99 on Monday. The business’s 50-day simple moving average is $1.98 and its 200-day simple moving average is $1.89. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.38. The stock has a market capitalization of $9.67 million, a P/E ratio of -0.58 and a beta of 1.57.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.19). Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%. The company had revenue of $0.12 million for the quarter.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.